Expert Interview
Discussing the recent FDA approval for Radicava ORS (edaravone) - orally administered version of Radicava on the treatment landscape of ALS
Ticker(s): MTPAInstitution: University of California San Francisco
- Assistant Program Director of the UCSF Neurology Residency.
- Manages patients with disorders of the nerve, muscle, neuromuscular junction, and spine.
- Cares for general Neurology patients at the Zuckerberg San Francisco General Hospital, and Neuromuscular and ALS patients in the Fresno region.
- Treats 45-50 patients with ALS
- Prescribed Evrysdi to 1 patient
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
